Linear Morphea‐Induced Atrophy Treated with Hyaluronic Acid Filler Injections by Choksi, Adrienne N. & Orringer, Jeffrey S.
Linear Morphea-Induced Atrophy Treated with Hyaluronic Acid
Filler Injections
ADRIENNE N. CHOKSI, MD, AND JEFFREY S. ORRINGER, MD
The authors have indicated no significant interest with commercial supporters.
Linear morphea in an en coup de sabre patternis a variant of localized scleroderma that
develops on the frontal or frontoparietal scalp.
Approximately two-thirds of cases occur before the
age of 18. The etiology is unknown, but the disease is
thought to be most likely autoimmune in nature.
Between 50% and 75% of these patients have been
found to have a positive serum antinuclear antibody
(ANA), although ANA positivity has not been noted
to correlate with disease activity.1,2 In en coup de
sabre morphea, trauma has also been cited as a
possible trigger.3 Although lesions may be limited to
the skin, en coup de sabre morphea is notorious for
extracutaneous involvement, and lesions may extend
deep into underlying tissues and may be associated
with neurologic, ophthalmologic, and oral
abnormalities.4
Linear morphea may be a self-limited disease, and
some regression or softening of skin lesions often
spontaneously occurs, although complete resolution
in en coup de sabre morphea is unusual. Treatment
of active, fibrotic disease often involves a variety of
topical or oral medications, phototherapy, or both.
Unfortunately, even once disease activity has sub-
sided, patients are often left with some degree of
noticeable skin atrophy. Lesions may leave disfigur-
ing atrophic scars that can be psychosocially dis-
tressing to patients. Surgical options are often
limited, but the use of soft tissue augmentation with
injectable fillers has been explored. We report a
case of facial linear morphea in an en coup de
sabre pattern successfully treated initially using
ultraviolet A (UVA1) phototherapy for active disease
followed by hyaluronic acid filler injections for
tissue contouring.
Case Report
A 20-year-old man presented to our clinic with an
approximately 4-year history of a linear depression
on the left side of his forehead, extending onto the
scalp. The area was asymptomatic but cosmetically
disfiguring, and the patient was interested in treat-
ment options to improve the appearance of the
affected skin. He had been seen in our department 3
years before, at which time he was diagnosed with
linear morphea in an en coup de sabre pattern, and
treatment with UVA1 was recommended for the
active, fibrotic phase of his disease. He underwent
approximately 22 treatments with UVA1 photo-
therapy. During the time of his UVA1 treatment
series, the patient’s disease activity halted, and sig-
nificant softening of the affected skin was noted, but
he was ultimately left with a residual atrophic linear
plaque on the left side of his forehead (Figure 1).
Because the patient’s linear morphea was no longer
felt to be inflammatory or active, no additional
treatment with UVA1 or systemic agents was
pursued. For the cosmetic disfigurement that
remained, we recommended injection of a
non-animal-based cross-linked hyaluronic acid soft
tissue filler (Perlane) to smooth the contours at
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the involved site and thus improve the cosmetic
appearance of the lesion. After local infiltration of
small volumes of 1% lidocaine with epinephrine in a
‘‘ring block’’ pattern to achieve anesthesia, a total of
1 mL of hyaluronic acid was injected into the lesion
using a linear threading technique, with an excellent
aesthetic result, including approximately 75%
improvement in the contour defect. (Only a single
syringe was used during the initial treatment session
at the patient’s request.) Cosmetic improvements
were immediate and sustained for at least 5 months.
After 5 months, the patient continued to have stable
improvement in the appearance of the atrophic skin,
but a mild residual contour defect was still present
(Figure 2). Therefore, a repeat injection of an
additional 1 mL of hyaluronic acid was given to
further enhance the cosmetic outcome (Figure 3). An
improvement in the original contour defect esti-
mated to be greater than 90% was achieved, and the
patient was very pleased with this clinical result.
Discussion
Morphea en coup de sabre is a type of linear
scleroderma that has a tendency to leave disfiguring
atrophic scars. A variety of treatments have been
used for linear morphea, with varying degrees of
success. Treatments consist of those intended to
inhibit the progression and inflammatory phase of
the disease and those to treat the residual atrophy
and disfigurement. Treatments used for the
inflammatory phase of the disease include topical,
intralesional, and systemic steroids; methotrexate;
tacrolimus ointment; calcipotriol ointment; and
phototherapy. UVA-1 has been found to be partic-
ularly effective in shortening the active period of the
disease and preventing disease progression.5
There has been a relative paucity of therapeutic
options for treating the residual atrophy that so often
remains after the inflammatory phase of the disease
has subsided. Previously described treatment
modalities employed to improve the appearance of
residual scarring include surgical procedures such
as resection of the lesion, implantation of porous
polyethylene implants, and AlloDerm tissue
matrix.6–8 Although cosmetic improvements have
been noted with such procedures, many of these
treatment methods carry significant risks, require a
substantial recovery period, or both. Other
less-invasive treatment modalities have been also
documented, with autologous fat grafting, tissue
cocktail injections, and poly-L-lactic acid injections
having been described in the literature.9–12 Auto-
logous fat transfer requires harvesting of fat from a
distant site and therefore necessitates an additional
procedure, whereas the use of poly-L-lactic acid
injections often requires several treatment sessions
for optimal results and involves delayed cosmetic
benefits. To our knowledge, cosmetic correction of
scarring resulting from linear morphea in an en coup
de sabre pattern using hyaluronic acid filler injec-
tions has not been previously reported.
Figure 1. A 20-year-old man with atrophic scarring of the
left side of his forehead secondary to linear morphea. The
atrophy extends from the mid-brow into the hairline.
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Hyaluronic acid fillers are typically used for correc-
tion of moderate to severe facial wrinkles and folds,
for which they are FDA approved, although fillers
are increasingly being used for off-label indications,
including facial contouring. Initial trials involving
another hyaluronic acid–based filler (Restylane)
have suggested a 6-month duration of effect, and a
more recent study showed persistent results up to 18
months after initial treatment with Restylane fol-
lowed by one re-treatment session.13 In addition to
their immediate contouring effects, studies of
hyaluronic acid fillers have demonstrated induction
of type I collagen in the dermis, which may lead to
prolonged cosmetic benefits.14 Although this may
ultimately also prove to be true of other fillers,
detailed molecular studies regarding this point are
currently lacking. Perlane, with its relatively large
particle size, is a robust hyaluronic acid filler shown
to be highly useful in the treatment of a variety of
soft tissue defects.15 It was selected in this case in the
hope of achieving maximal aesthetic benefits with
the smallest volume possible in our patient, who had
financial constraints that limited the amount of filler
we could use in a single treatment session. In addi-
tion, the theoretical reversibility of hyaluronic acid
fillers due to the availability of hyaluronidase made
Perlane an attractive treatment option.
Among the potential but rather uncommon compli-
cations of hyaluronic acid filler use are injection into
or compression of vessels, causing tissue necrosis;
persistent nodule or granuloma formation; allergic
reactions; infection; and persistence of a visible
blue hue.15 With respect to the first, care was
taken to avoid inadvertent injection into the tem-
poral or supraorbital vessels during the treatment.
Figure 2. (A) Sustained aesthetic improvement 5 months after injection of hyaluronic acid. (B) Close-up view of treated area.
Figure 3. Enhanced aesthetic outcome 2 weeks after a sec-
ond hyaluronic acid injection session.
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Reactivation of morphea due to antigenic stimula-
tion with subsequent progression of the lesion
constitutes a theoretical additional possible compli-
cation of hyaluronic acid filler injections for
lesions of linear morphea. The benefits of hyaluronic
acid filler injections for correction of scarring due to
linear morphea include ease of injection, ready
availability of adequate filler material, and the fact
that it can be administered in a single treatment
session on an outpatient basis with essentially no
social downtime.
The cosmetic outcome in our patient has thus far
been excellent. Our patient had developed a signifi-
cant amount of softening of his lesion during treat-
ment with UVA1 phototherapy, which allowed for
maximal aesthetic benefits with the hyaluronic acid
filler injections. It is probably wise to attempt cor-
rection of these lesions only once disease activity
appears to be quiescent, although patients should be
warned that the inflammatory phase of their disease
could reactivate at any time, negating the effects
of cosmetic corrective treatments, requiring the use
of other medical therapies, or both. We believe that
hyaluronic acid injections are an excellent thera-
peutic option for aesthetic improvement of scarring
in linear morphea and may be a useful alternative to
more invasive surgical procedures.
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